Trial Profile
Randomized Phase II Study of Docetaxel (T) with or without Capecitabine (X) as Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) (OOTR N003).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 15 Sep 2015 Status changed from active, no longer recruiting to completed as per full results were already published in Pubmed [PMC3825616]
- 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
- 26 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan